The domestic DPP-4i diabetes treatment market, which is formed at 600 billion won a year, slowed down last year. It recorded the lowest growth rate in the last seven years. In the DPP-4 inhibitor market, where growth has slowed, the position of domestic companies has also expanded significantly. Rx sales for foreign company products fell.

◆DPP-4 inhibitor, growth rate of 1% in 7 years

According to UBIST, a pharmaceutical market research firm, on the 19th, the total market for DPP-4 inhibitors last year was 611.3 billion won, up 1.3% from a year earlier. The growth rate of the DPP-4 inhibitor market is the lowest since 2014.

In the past seven years, the market for DPP-4